Related Experiment Videos
Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression
R Lotan1, Y Matsushita, D Ohannesian
1Department of Tumor Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Carbohydrate Research
|June 25, 1991
Summary
The L-31 lactose-binding lectin increases with colorectal cancer stage, unlike L-14.5. Higher L-31 levels in tumors correlate with distant metastases, indicating its clinical relevance in colon cancer progression.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Lactose-binding lectins (L-14.5 and L-31) are present in vertebrate tissues, including normal and cancerous colon.
- These lectins have potential clinical relevance in human colorectal carcinoma.
Purpose of the Study:
- To investigate the clinical significance of lactose-binding lectins in human colon cancer.
- To correlate lectin levels with Dukes' stages of colorectal carcinoma.
Main Methods:
- Analysis of 46 colorectal carcinoma specimens using immunoblotting.
- Quantification of L-31 and L-14.5 lectins.
- Immunohistochemical staining to determine lectin localization.
Main Results:
- L-31 lectin levels were significantly higher in advanced Dukes' stage D tumors (distant metastases) compared to earlier stages (B1, B2).
- L-14.5 lectin levels showed minimal variation and no correlation with cancer stage.
- L-31 was localized in the cytoplasm of carcinoma cells, while L-14.5 was associated with secreted material.
Conclusions:
- The amount of L-31 lectin increases with colorectal cancer progression and malignancy.
- L-31 lectin shows potential as a biomarker for advanced colorectal cancer.